203 related articles for article (PubMed ID: 36870358)
21. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
22. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
23. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
[TBL] [Abstract][Full Text] [Related]
24. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
25. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
26. EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia.
Rankine-Mullings AE; Little CR; Reid ME; Soares DP; Taylor-Bryan C; Knight-Madden JM; Stuber SE; Badaloo AV; Aldred K; Wisdom-Phipps ME; Latham T; Ware RE
JMIR Res Protoc; 2016 Sep; 5(3):e185. PubMed ID: 27619954
[TBL] [Abstract][Full Text] [Related]
27. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
28. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
[TBL] [Abstract][Full Text] [Related]
29. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.
Hankins JS; McCarville MB; Rankine-Mullings A; Reid ME; Lobo CL; Moura PG; Ali S; Soares DP; Aldred K; Jay DW; Aygun B; Bennett J; Kang G; Goldsmith JC; Smeltzer MP; Boyett JM; Ware RE
Am J Hematol; 2015 Dec; 90(12):1099-105. PubMed ID: 26414435
[TBL] [Abstract][Full Text] [Related]
30. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
[TBL] [Abstract][Full Text] [Related]
31. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
Smart LR; Segbefia CI; Latham TS; Stuber SE; Amissah-Arthur KN; Dzefi-Tettey K; Lane AC; Dei-Adomakoh YA; Ware RE
Trials; 2023 Sep; 24(1):603. PubMed ID: 37737189
[TBL] [Abstract][Full Text] [Related]
32. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.
Bernaudin F; Verlhac S; Arnaud C; Kamdem A; Hau I; Leveillé E; Vasile M; Kasbi F; Madhi F; Fourmaux C; Biscardi S; Gluckman E; Socié G; Dalle JH; Epaud R; Pondarré C
Blood; 2016 Apr; 127(14):1814-22. PubMed ID: 26851292
[TBL] [Abstract][Full Text] [Related]
35. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
[TBL] [Abstract][Full Text] [Related]
36. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
37. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
[TBL] [Abstract][Full Text] [Related]
38. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
39. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
40. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
